SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 6

Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats

Yusuf HANÇERLİ
MUSTAFA KAPLAN
ALPASLAN TANOĞLU
Soner YEŞİLBAŞ
Zafer KÜÇÜKODACI
Muhammet YILDIRIM
Gizem NARLI
YUSUF SERDAR SAKİN
Pages
485–491
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).Conclusion: Our study points out that tocilizumab may be an effective agent for pancreatitis treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality.
📊
Key Findings & Data:In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.Materials and Methods: Forty-eight rats were divided into six groups for this study.
💡
Conclusion & Impact:Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).Conclusion: Our study points out that tocilizumab may be an effective agent for pancreatitis treatment
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.Materials and Methods: Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.Results: A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p<0.0001). Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).Conclusion: Our study points out that tocilizumab may be an effective agent for pancreatitis treatment

🔖

Cite This Article

HANÇERLİ, Y., KAPLAN, M., TANOĞLU, A., YEŞİLBAŞ, S., KÜÇÜKODACI, Z., YILDIRIM, M., NARLI, G., SAKİN, Y. S. (2017). Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 6, 485–491. https://ajindex.com/articles/410192

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008; 92: 889-923
  2. Sah RP, Dawra RK, Saluja AK. New insights into the pathogenesis of pancreatitis. Curr Opin Gastroenterol 2013; 29: 523-30
  3. Sah RP, Garg P, Saluja AK. Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol 2012; 28: 507-15
  4. Steer ML. Pathogenesis of acute pancreatitis. Digestion 1997; 58: 46-9
  5. Sweiry JH, Mann GE. Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol Suppl 1996; 219: 10-5
  6. Yonetci N, Sungurtekin U, Oruc N, et al. Is procalcitonin a reliable marker for the diagnosis of infected pancreatic necrosis? ANZ J Surg 2004; 74: 591-5
  7. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol 1977; 373: 97-117
  8. Niederau C, Ferrell LD, Grendell JH. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology 1985; 88: 1192-204
  9. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96
  10. Schoenberg MH, Buchler M, Gaspar M, et al. Oxygen free radicals in acute pancreatitis of the rat. Gut 1990; 31: 1138-43
  11. Greenberg JA, Hsu J, Bawazeer M, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg 2016; 59: 128-40
  12. Steer ML, Meldolesi J. The cell biology of experimental pancreatitis. N Engl J Med 1987; 316: 144-50
  13. Strowski MZ, Sparmann G, Weber H, et al. Caerulein pancreatitis increases mRNA but reduces protein levels of rat pancreatic heat shock proteins. Am J Physiol 1997; 273: G937-45
  14. Tanoglu A, Yazgan Y, Kaplan M, et al. Trimetazidine significantly reduces cerulein-induced pancreatic apoptosis. Clin Res Hepatol Gastroenterol 2015; 39: 145-50
  15. Konturek PC, Dembinski A, Warzecha Z, et al. Comparison of epidermal growth factor and transforming growth factor-beta1 expression in hormone-induced acute pancreatitis in rats. Digestion 1998; 59: 110-9
  16. Inagaki T, Hoshino M, Hayakawa T, et al. Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis. Pancreas 1997; 14: 1-8
  17. Cosen-Binker LI, Gaisano HY. Recent insights into the cellular mechanisms of acute pa